Genentech's $122M MS Drug Royalties Case Ends In Mistrial

A California federal judge declared a mistrial Thursday after jurors reached an impasse in Genentech Inc.'s $122 million breach of contract case over patent royalties from sales of Biogen MA Inc.'s...

Already a subscriber? Click here to view full article